我国药品支付价格形成及谈判定价中引入卫生技术评估的路径探讨

Exploration the Introduction of HTA in Drug Paying Price Formation and Pricing Negotiation in China

目的:为完善我国药品价格制定制度提供政策建议。方法:综合运用文献法和比较研究法,结合公共政策和卫生技术评估(HTA)的原理和方法,分析国际药品定价制度的经验以及我国药品定价存在的问题。结果:我国药品定价机制经过了"全管-放开-管制-逐步放开"的过程。韩国将HTA引入医保支付价格制定程序,而法国则将其引入谈判定价程序。结论:建议相关部门构建药品价格形成机构的战略发展目标,实行分步走策略,明确优先使用HTA的药物类型,建立科研支撑网络,构建相关数据库及研究平台,开展相关人才培养等。

OBJECTIVE： To provide policy recommendations on the pharmaceutical pricing system in China.METHODS：We applied a mixture of methods including content analysis and comparative research methods, combining with principles and methods of public policy and health technology assessment（HTA）, in the analysis of international experience in pharmaceutical pricing systems and the existing problems of China＇ s pricing system.RESULTS ： the drug pricing mechanism in our country through the＂whole tube-open-control-gradually let go＂ of the process. South Korea will paid the price establishment procedure, introduced the HTA; while France put HTA into the negotiation pricing procedure.CONCLUSIONS： Specific recommendations include to build a clear strategic development goal for drug price formation mechanism; to approach implementation step by step; to begin with carefully selected types of drugs; to build a supporting scientific research network; to build supporting databases and platforms; to build capacity.